Skip to main content
B

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 Shenzhen Stock Exchange Manufacturing
Filings indexed 1,650 across all filing types
Latest filing 2024-11-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第四届监事会第十六次会议决议公告
Regulatory Filings
2024-11-01 Chinese
第四届董事会第十九次会议决议公告
Regulatory Filings
2024-11-01 Chinese
关于归还用于暂时补充流动资金的闲置募集资金的公告
Regulatory Filings
2024-11-01 Chinese
2024年三季度报告
Regulatory Filings
2024-10-28 Chinese
2024年第三季度报告披露提示性公告
Regulatory Filings
2024-10-28 Chinese
关于股东股份质押变动的公告
Regulatory Filings
2024-10-24 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.